文献速递MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

骨髓纤维化与骨髓增生异常综合征的异基因干细胞移植:当代综述

Allogeneic Stem Cell Transplant for Myelofibrosis and Myelodysplastic Syndromes: A Contemporary Review.
PubMed 文献 · Am J Hematol · 2025-03-13

异基因造血干细胞移植(HCT)仍是骨髓增生异常肿瘤(MDS)和骨髓纤维化(MF)唯一可能治愈的手段,也是符合条件的高危患者的标准治疗。本文综述了两种疾病在基因组分层、移植时机、分子可测量残留病监测及移植管理方面的最新进展与推荐。

要点

  • 异基因HCT是MDS和MF唯一可能治愈的疗法,为符合条件的高危患者的标准治疗。
  • MDS中基因组分析革新了IPSS-M等预后框架,支持个体化治疗决策。
  • MF中驱动突变(JAK2、CALR、MPL)及额外高危分子标志物提供疾病生物学与移植结局的关键信息。

核心结论

  • 异基因HCT仍是MDS和MF唯一可能治愈的疗法,也是符合条件的高危患者的标准治疗。
  • 利用分子技术、临床经验、以患者为中心的决策及创新药物策略,有望构建变革性的治愈性治疗框架。

研究设计与样本

  • 本文为当代综述,汇总MDS和MF异基因HCT的疾病生物学、标准治疗、推荐及开放研究方向。

主要发现

  • MDS中基因组分析革新了IPSS-M等预后框架,使治疗决策得以个体化。
  • MF中驱动突变(如JAK2、CALR、MPL)及额外高危分子标志物提供疾病生物学和移植结局的关键信息。
  • 分子可测量残留病监测在两种疾病中均显示预后价值,可指导抢先策略以降低复发风险。
  • 最佳HCT时机至关重要,近期模型可能有助于个体化治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic hematopoietic stem-cell transplantation (HCT) remains the only potentially curative therapy for patients with myelodysplastic neoplasms (MDS) and myelofibrosis (MF) and is the standard care for eligible patients with higher-risk disease. Despite significant advancements, both diseases pose unique challenges due to their clinical and molecular heterogeneity, necessitating personalized approaches to patient selection, timing, and transplant management. For MDS, genomic profiling has revolutionized prognostic frameworks such as IPSS-M, enabling tailored therapeutic decisions. In MF, driver mutations (e.g., JAK2, CALR, MPL) and additional high-risk molecular markers provide critical insights into disease biology and transplant outcomes. Optimal timing of HCT is critical, and recent models might help personalize treatment approaches. Molecular measurable residual disease monitoring has demonstrated prognostic value in both diseases, guiding preemptive strategies to mitigate relapse risk. Harnessing molecular technologies, clinical expertise, patient-centered decision-making, and innovative pharmaceutical strategies offers an exciting opportunity to shape a transformative and curative treatment framework. Here, we provide a contemporary review on HCT for MDS and MF, highlighting up-to-date insights into disease biology, standard of care, and recommendations, as well as open avenues.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Gagelmann N, Kröger N. Allogeneic Stem Cell Transplant for Myelofibrosis and Myelodysplastic Syndromes: A Contemporary Review. Am J Hematol. 2025. PMID: 40079242. doi:10.1002/ajh.27660

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。